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ABSTRACT  
Ocuserts or Ophthalmic inserts are sterile preparations containing drug as dispersion or as solution in the polymeric support. The sulbactum is 
highly used as antibacterial agent in combination with other antibacterial agent. This study aims to formulate novel sulbactum ocuserts to 
enhance patient compliance through providing controlled drugs release from polymeric matrix. Ocuserts were prepared by solvent-casting 
method using different polymers HPMC, K4M, Polyvinyl alcohol,ethyl cellulose as polymer gelatine and propylene glycol and dibutyl phthalate 
as plasticizer in different ratios. The prepared ocusters were physic-chemichally evaluated for their weight, thickness, drug content uniformity, 
surface pH, swelling index (SI) and folding endurance. The viscosity of the polymeric solution used for the formulations was determined using 
Brookfield viscometer. In-Vitro Drug Release study and Accelerated stability studies were also performed. The prepared ocuserts show uniform 
weight, thickness and drug content. Their surface pH was in the physiological range and showed acceptable folding endurance. HPMC formulas 
had higher SI values. Results of in-vitro testing for one of the prepared ocuserts shows slow release of drugs up to 24 hours. One of the prepared 
ocuserts is promising for once-daily effective and safe drug delivery system of sulbactum for glaucoma treatment.  
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Ophthalmic drug delivery is one of the most interesting and 
challenging endeavors facing the pharmaceutical 
researchers1. Ocuserts augments contact time, longrunning 
duration of action, improves bioavailability, diminishes the 
frequency of administration and therefore achieves good 
patient compliance. It is also outlook to administer the drug 
to inflamed eye due to sustained release of the medicament 
from ocuserts. Furthermore, ocuserts are beneficial in saving 
time to the healthcare professionals. The efficacy of any 
ophthalmic preparation depends on the tissues for providing 
hoped therapeutic response2. The advantage of ocular 
inserts, which are solid devices placed in the cul-de-sac of the 
eye in comparison with liquid formulations are numerous. 
Because of the prolonged retention of the devices and a 
controlled release, the effective drug concentration in the eye 
can be ensured over an extended time period. Dosing of the 
drug is also more accurate and the risk of systemic side-
effects is decreased3. Viral conjunctivitis and bacterial 
conjunctivitis may affect one or both eyes. Viral 
conjunctivitis usually produces a watery or mucous 
discharge. Bacterial conjunctivitis often produces a thicker, 
yellow - green discharge and may be associated with a 
respiratory infection or with a sore throat4. Sulbactam, a new 
3-lactamase inhibitor, has pharmacokinetic characteristics in 
humans similar to those of ampicillin and amoxicillin. 
Sulbactam is a semisynthetic β -lactamase inhibitor which 
when combined with certain β-lactam antibacterials extends 
their activity against bacteria that are normally resistant to 
the antibiotic due to production of β -lactamases. In 
combination with ampicillin, it extends the antibacterial 
activity of ampicillin to include β-lactamase-producing 
strains which are otherwise resistant, including Bacteroides 
fragilis, and increases the susceptibility of many sensitive 
strains5. Sulbactam is poorly absorbed after oral 
administration and sulbactam/ampicillin is therefore 
administered parenterally, although another linked 
sulbactam-ampicillin compound, sultamicillin, has been 
developed which is well absorbed after oral administration6. 
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The basic pharmacokinetic characteristics of sulbactam after 
parenteral administration are similar to those of ampicillin. 
Sulbactam is poorly absorbed orally7-8.This is an alternate 
approach to improve the bioavailability is the use of 
polymeric solutions, which change to a gel as a result of 
exposure to the physiological temperature, pH or ionic 
composition of lacrimal fluid. 
MATERIALS AND METHODS 
Chemicals 
Sulbactum, HPMC, K4M, Polivinyl Alcohol and Dibutyl 
phthalate procured from Nellu medicare, New delhi.  Gelatin, 
Ethyl cellulose and Propylene glycol were obtained from 
CDH Pvt Limited New Delhi. All solvents and reagents were 
of analytical grade. 
Method of film preparation 
The 15 formulations were prepared using various steps. The 
different formulation of sulbactum ocusert is given in table 1. 
The ocuserts were prepared by solvent casting. Sulbactum 
was accurately weighed and dissolved in distilled water. Pre-
determined polymer was weighed and dissolved in distilled 
water separately in another beaker. Then clear drug solution 
was poured into polymer solution with constant stirring to 
get a homogeneous solution. Required amount of propylene 
glycol was added and mixed well. The resulting solution was 
prepared by casting method. Films are allowed to dry at 
room temperature for 48hr, after complete drying the films 
were cut with of cork borer of size 8mm so that each 
ocuserts will contain 1mg of the drug. 
  





Drug reservoir Plasticizer  Rate controlling 
 DRUG HPMCK4M  PVA  GELATIN  RATIO  
 SB1 40   40  - -   1:1 30% w/w of the dry 
polymer 
4% 
 SB2 40   40  -  -  1:1 6% 
 SB3 40   60  -  -  1:1.5 4% 
 SB4 40   60  -  -  1:1.5 6% 
 SB5 40   80  -  -  1:2 4% 
 SB6 40   80  -  -  1:2 6% 
 SB7 40   -  40  -  1:1 4% 
 SB8 40   -  40  -  1:1 6% 
 SB9 40   -  80  -  1:2 4% 
 SB10 40  -   80  -  1:2 6% 
 SB11 40   -  -  40  1:3 4% 
 SB12 40   -  -  40  1:3 6% 
 SB13 40   -  -  60  1:1 4% 
 SB14 40   -  - 60  1:1 6% 
 SB15 40   -  - 80   1:1.5 4% 
 
 
Preparation of the rate controlling membrane  
Ethyl cellulose was dissolved in chloroform. Required 
quantitiy of dibutyl phthalate was added and stired until to 
get a clear solution. Then it was poured over a clear glass 
plate and allowed to dry. 
Sealing 
The prepared rate controlling membrane and drug reservoir 
were cut into circular shape by using special mould after 
sufficient drying. The drug –matrix films were kept and fixed 
in between the rate controlling membrane.  The ocuserts 
containing sulbactum is shown in Figure 1. 
 
 
Fig.1 Prepared ocuserts 
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Evaluation of ocular inserts  
The prepared ocular inserts were evaluated for the following 
parameters as described below. 
Physical appearance  
All the formulated ocular inserts were evaluated for the 
physical characters such as size, shape, colour and 
smoothness. 
Uniformity of thickness  
Films were evaluated for the thickness using a vernier 
calliper .The average of three readings was taken at different 
points of films, and the mean thicknes aws calculated .The 
standard deviations (SD s) in thickness were computed from 
the mean value. 
Weight Variation  
The weight variation test was carried out using electronic 
balance by weighing 3 patches from each formulation. The 
mean value was calculated, and the standard deviations of 
weight variation were computed from the mean value. 
Folding Endurance  
The folding endurance is expressed as the no of folds 
(number of times the insert is folded at same place ) either 
to break specimen or to develop visible cracks .This test is 
important to check the ability of sample to with stand 
folding .This can also give an indication of brittleness . The 
specimen was folde in centre, between the fingers and 
thumbs and then opened.This was termed as 1 folding. This 
process was repeated till the insert showed breakage and 
cracks in centre of insert. The total folding operation was 
named as folding endurance value9. 
Surface pH  
Insert film were allowed to swell for 30 minutes in 1 ml of 
distilled water. These swollen films were then removed and 
placed under digital p H meter to determine surface pH. 
Swelling index  
Initially films were weighed and placed separately in 
beakers containing 4 ml distilled water. At regular intervals 
of time (every 10 minutes) the films were removed and 
excess water on their surface was removed using filter paper 
and in weight . It was then calculated as:  
       Swelling Index =  Final weight – Initial weight x 100  
                                                      Initial weight  
Estimation of percentage moisture absorbed  
The percentage moisture absorbtion test was carried out to 
check physical stability or integrity of ocular films. Ocular 
films were weighed and placed in desiccators containing 100 
ml of saturated solution of aluminium chloride. After three 
days the ocular films were taken out and reweighed. The 
percentage moisture absorption was calculated using the 
following equation10.  
Percentage moisture absorption=Final weight – Initial weight x100 
                                                                    Initial  weight     
Drug content  
For drug content uniformity, the ocuserts were placed in 5 
ml of p H 7.4 phosphate buffer and were crushed to extract 
the drug from ocuserts. The solution was filtered through a 
Whitman’s filter paper and filtrate was suitably diluted with 
buffer solution. The absorbance of the resulting solution was 
measured at 259 nm.  
In vitro diffusion study  
The drug release pattern from the ocusert was studied by 
using a semipermeable membrane that is chorioallantoic 
membrane from the egg which acts as a corneal epithelium. 
In vitro diffusion of the drug from different ocular inserts 
was studied using diffusion cell. In the donor compartment 
of the cell ocular insert was placed and in receptor 
compartment phosphate buffer (p H 7.4 ) is place and in 
receptor compartment phosphate buffer (PH 7.4) is place .in 
order to simulate the tear volume, 0.7ml of phosphate buffer 
(p H 7.4 ) was placed and maintain at the same level 
throught the study. Egg membrane (semipermeable 
membrane) was placed between both the compartments. 
The surface of the membrane was in contact in media in 
receptor compartment the media us receptor compartment 
is stirred continuously using a magnetic stirrer and 
temperature was maintained 37 + 0.50C. At definite time 
intervals, 3ml of aliquots were analyzed spectrophoto-
metrically at λmax 259 nm12. 
 Accelerated stability study 
 Stability of the pharmaceutical preparation can be defined 
as “the capability of a particular formulation in a specific 
system to remain within its physical, chemical, 
microbiological, therapeutic and toxicological specifications 
throughout its shelf life.” The purpose of stability testing is 
to provide evidence on how the quality of a substance or 
drug product varies with time under the influence of a 
variety of environmental factors such as temperature, 
humidity, and light, enabling recommended storage 
condition, re-test periods and self lives to be established.  In 
the presence study, the formulation was selected for the 
study, and  ocuserts were packed in amber- colored bottles 
tightly plugged with cotton and capped. They were exposed 
to various to various temperatures (370 C, 500 C, 40 C) for a 
period of one month. Films were evaluated for physical 
appearances, weight variation, thickness, drug content12.             
RESULTS  
Physical appearance  
The fabricated film was thin, transparent and visually 
smooth surface. The drug and polymer distribution is 
uniform.
 
Table 2. Characterisation of sulbactum 
Test  Specification  Observations    Remarks  
Description  White powder  White powder  Complies  
Solubility  It is freely soluble in water, 
methanol  
It was soluble in water  Complies  
Odour  Odourless  Odourless  Complies  
Melting point  150-200oC 170 Complies 
LOD  NMT 1% 0.52% Complies 
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Thickness uniformity  
The thickness of drug loaded film was measured at three 
different points  with the help of vernier caliper, result was 
given in table 3 and the result indicate that prepared 
ocuserts were uniform in thickness. 
Uniformity of weight 
Drug loaded films were tested for uniformity in weight and 
the results was given in table 5.6, indicate that the uniform 
distribution of drug and polymer. 
 Folding endurance test  
The recorded folding endurance test was found to be in the 
range of 200-300. This indicates the flexibility of the films; 
results were given in table 3  
Surface pH  
Surface pH of all the formulation was measured using digital 
pH meter values were given in table 3. The surface pH of all 
the formulation was neutral so no eye irritation was 
expected.
 
Table 3. Results of thickness, weight variation, folding endurance and surface pH 
 Batch Thickness (mm) Weight variation 
(mg)  
Folding 
endurance   
Surface pH  
 SB1  0.25 ± 0.0  24.3 ± 0.1  215±2.9 6.89±0.0  
 SB2  0.19 ± 0.0  23.5±0.6  195±7.2  7.32±0.1 
 SB3  0.2 ± 0.1  25.6±0.3  220±5.3  7.65±0.2 
 SB4  0.21 ± 0.3  25.02±0.3  230±2.7  6.76±0.1 
 SB5  0.25 ± 0.1 21.68±0.5  215±2.9 6 .89±0.2 
 SB6  0.26 ± 0.2  24.3±0.1  225±3.9  7.12±0.1 
 SB7  0.21 ± 0.2 22.09±0.3  275±2.6  7.01±0.2 
 SB8  0.24±0.1  23.05±0.3  230±5.0  7.28±0.5 
 SB9  0.26±0.1  26.03±0.2  258±3.5  6.89±0.3 
 SB10  0.31±0.1  24.1±0.5  267±2.3  6.66±0.01 
 SB11  0.24±0.1  25.07±0.01  226±4.3  7.3±0.2 
 SB12  0.25±0.2  27.51±0.4  229±4.1  7.33±0.2 
 SB13  0.32±0.1  25.08±0.2  222±0.3  7.23±0.1 
 SB14  0.33±0.1  28.51±0.4  198±.72  6.78±0.3 
 SB15  0.33±0.2  28.51±0.3  198±.70  6.78±0.32 
 
Swelling index 
The swelling of drug loaded films in 4 ml double distilled water was observed till 60 min.The data for increased in weight were 
given in table no 4.  
Table 4. Results of swelling index 
Time (min) Batch 
SB1 SB2 SB 3 SB4 SB5 SB6 SB7 SB8 
0 0 0 0 0 0 0 0 0 
10 15.1% 10.2% 20.3% 18.1% 12.8% 15.6% 14.2% 17.6% 
20 33.5% 18.6% 27.8% 25.2% 19.4% 21.6% 20.3% 24.5% 
30 45.5% 25.2% 36.6% 32.3% 26.5% 29.7% 26.8% 32.8% 
40 57.5% 30.5% 45.8% 39.5% 35.8% 36.5 32.6% 41.5% 
50 63.5% 45.8% 50.8% 46.7% 32.2% 37.3% 42.5% 47.2% 
60 70.2% 47.8% 56.3% 50.3% 52.3% 41.3% 51.3% 55.6% 
 
 Time (min) Batch 
SB9 SB10 SB 11 SB12 SB13 SB14 SB15 
0 0 0 0 0 0 0 0 
10 22.1 % 10.2% 15.6% 17.1% 20.1% 21.2% 15.23% 
20 28.6% 14.7% 20.1% 22.5% 26.7% 23.8% 23.0% 
30 35.2% 20.6% 25.1% 28.6% 33.5% 36.6% 24.2% 
40 42.5% 25.7% 32.2% 35.4% 40.5% 44.6% 36.2% 
50 49.9% 30.8% 39.4% 42.3% 45.6% 50.6% 47.5% 




Dhaka et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2020; 10(1-s):66-71 
ISSN: 2250-1177                                                                                  [70]                                                                                 CODEN (USA): JDDTAO 
Percentage moisture absorbed  
The percentage moisture absorbed was determined and the 
results were shown in table 5  
Percentage moisture loss  
The percentage moisture loss was determined and the 
results were shown in table 5 
Drug Content  
 In order to make sure the uniform dispersion of drug in 
films, drug content test was carried out. Drug content was 
analysed by UV spectroscopy at lemda max 259 using blank 
sample as reference sample. The percentage drug content 
result was given in table 5 
Viscosity  
As ration of drug polymer and the percentage of ethyl 
cellulose vary, there was a slight variation in the viscosity of 
all the formulation was observed viscosity of all the 
formulation was in the range of 56.4 to 70.2 cp. It initialized 
that it had good adhesion with the conjunctiva.
 
Table 5. Results of moisture absorbed, moisture loss,  drug content and viscosity 
Batch %Moisture absorbed % Moisture loss %Drug content Viscosity (Cp) 
SB 1 4.8±0.2 4.8±0.3 92.6±0.2 62.1 
SB 2 3.7±0.1 3.1±0.2 95.5±0.3 66.2 
SB 3 5.6±0.1 5.5±0.1 92.2±0.4 66.3 
SB 4 4.4±0.1 5.7±0.1 93.5±0.6 64.7 
SB 5 6.7±0.2 7.3±0.1 97.6±0.4 66.2 
SB 6 4.2±0.1 4.2±0.1 94.7±0.8 66.5 
SB 7 4.8±0.2 5.1±0.1 95.2±0.9 69.8 
SB 8 4.3±0.1 5.8±0.2 95.8±0.7 41.4 
SB 9 5.2±0.1 6.5±0.5 96.2±0.7 45.3 
SB 10 4.7±0.1 5.8±0.0 97.3±0.6 49.4 
SB 11 5.3±0.1 5.6±0.1 98.2±0.9 52.2 
SB 12 4.5±0.1 4.8±0.2 97.3±0.5 55.6 
SB 13 6.3±0.2 5.6±0.2 96.4±0.9 60.3 
SB 14 4.6±0.2 6.1±0.1 94.7±0.8 62.3 
SB 15 4.2±0.2 6.1±0.6 92.6±0.2 62.1 
 
In-Vitro Drug Release study  
The in-vitro drug release study of sulbactam ocuserts was 
carried out the using egg membrane as semipermeable 
membrane in phosphate buffer pH 7.4. The apparatus was 
designed with the objective of mimicking the conditions of 
ocular activity to certain extent. The release a data were 
given in table no. 6 
 
Table 6. Results of In-Vitro Drug Release study of sulbactam 
 
Time (hrs)  Cumulative  % drug release 
SB9 SB 10 SB11 SB12 SB13 SB14 SB15 
0 0 0 0 0 0 0 0 
1 11.8±0.09 9.0±0.3 16.6±0.3 22.3±0.9 24.7±0.3 10.5±0.9 22.7±0.3 
2 15.2±0.4 15.4±0.4 24.1±0.1 32.5±0.7 32.4±0.6 16 .4±0.4 26.5±0.2 
3 26.6±0.3 19.6±0.6 31.3±0.7 37.2±0.4 46.1±0.2 23 .4±0.5 29.6±0.3 
4 30.5±0.2 28.4±0.5 35.0±0.1 44.5±0.9 49.8±0.3 26.4±0.6 30.4±0.6 
5 34.6±0.5 32.2±0.1 42.5±0.9 51.1±0.2 54.4±0.8 33.9±0.3 35.0±0.3 
6 40.4±0.4 35.6±0.6 48.6±0.8 55.4±0.6 57.4±0.3 38.3±0.5 45.1±0.3 
7 45.3±0.3 41.3±0.7 52.4±0.6 62.8±0.3 60.9±0.4 40.1±0.6 46.4±0.7 
8 47.5±0.6 45.6±0.8 54.9±0.4 68.4±0.6 70.4±0.6 44.8±0.9 49.9±0.4 
9 48.5±0.3 51.8±0.5 59.5±0.6 73.4±0.6 74.6±0.6 47.5±0.3 52 .3±0.5 
 
Cumulative  % drug release 
Time (hrs) 
SB1 SB2 SB3 SB4 SB5 SB6 SB7 SB8 
0 0 0 0 0 0 0 0 0 
1 2.17±0.90 6.34±0.132 16.8±0.43 15.1±0.12 11.8±0.35 13.8±0.27 10.3±0.33 14.3±0.45 
2 6.09±0.45 6.3±0.13 27.60.1 27.30.7 19.5±0.2 20.7±0.4 19.9±0.3 22.3±0.1 
3 9.23±0.89 27.5±0.03 30.60.3 31.60.2 24.7±0.4 29.4±0.3 28.4±0.5 27.6±0.2 
4 10.6±0.21 28.5±0.7 34.9±0.2 36.2±0.3 28.2±0.4 32.4±0.6 30.4±0.6 31.4±0.6 
5 17.1±0.08 29.8±0.5 37.4±0.6 41.8±0.2 32.4±0.5 34.2±0.4 34.1±0.4 35.7±0.2 
6 20.1±0.02 31.9±0.6 41.8±0.2 47.7±0.4 34.2±0.6 36.5±0.9 38.9±0.5 37.9±0.6 
7 24.5±0.02 39.3±0.3 47.6±0.2 49.9±0.3 36.0±0.6 40.5±0.8 40.6±0.6 44.2±0.3 
8 28.6±0.06 42.0±0.4 50.6±0.3 54.2±0.4 39.2±0.3 44.6±0.4 42.9±0.6 50.4±0.3 
9 30.4±0.01 46.5±0.2 55.8±0.4 57.0±0.4 43.8±0.6 47.6±0.5 43.4±0.4 53.7±0.3 
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Accelerated stability studies 
The optimized formulation was subjected to short term 
stability testing. Films wrapped in aluminium foil and kept in 
a humidity chamber maintain at 370 C and 500C and 40C of 
period of 1 month at different temperature as per ICH 
guidelines. Results on stability study were given in table 7. 
From the above results there are a slight change occurs at a 
temperature of 500 C and there is no significant change was 
observed at other temperature. 
 
Table 7. Results of accelerated stability studies 
Temperature(oC) Evaluation Parameters 
Physical appearance Weight 
variation(mg) 
Thickness(mm) Drug content(mg) 
37 No change 25.2 0.2 1.0 
50 No change 25.1 0.2 0.9 
4 No change 25.2 0.2 1.0 
 
DISCUSSION 
Sulbactum drug is used against many diseases7. It is 
indicated for eye diseases. In the present study an attempt 
was made to develop various batches of sulbactum ousters 
using solvent casting method and they were evaluated. 
Polymers such as HPMC, K4M, PVA, Ethyl cellulose and 
gelatin were good film forming polymer. The percentage of 
ethyl cellulose provided a sustained release of the drug from 
polymeric reservoir. The results of the drug compatibility 
studies revealed that there was no chemical interaction 
between the pure drug and the excipients used. In evaluation 
parameters, the viscosity of all formulation was found to be 
in between 50 to 72.3 cp. It is indicate that it has good 
adhesive with the conjunctiva. The thickness of all the films 
was to be in the range of 0.180 to 0.323mm which  shows 
that it is easily inserted in to the eye and does not  produce 
any irritation  in eye, weight of all the films were found to in 
between 20.01 to 28.02 mg which that there is uniform 
distribution of the drug and polymer,  folding endurance  al 
the formulation were to be in the range of 200-300 and the 
surface pH of all the formulation was found to be in range 
6.60-7.5, compatible with the tear fluid pH that is 7.4. which 
shows that the preparations are sterile and safe to be used in 
the eye. All these results showed that ocuserts prepared 
compatible with the eye and does not produce any 
inflammation or redness in the eye. In-vitro drug release 
from SB ocuserts in phosphate buffer p H 7.4. The optimized 
SB 10 showed 87% drug release.  
CONCLUSIONS 
From the experimental findings it had been concluded that 
the said promising batch SB10 would be able to benefits such 
as increase residence time, prolong drug release, reduction 
in the frequency of administration and thereby may help to 
improve the patient compliance with the limitation that the 
formulation is non-erodible. The drug remained intact and 
stable in the ocuserts as well as in the storage with no 
apparent chemical interaction between the drug and 
excipients in future further work will be progress to 
establish the therapeutic utility of these systems by 
pharmacokinetic and pharmacodynamics studies in humans. 
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